Accuray (NASDAQ:ARAY – Get Rating) and Nexgel (NASDAQ:NXGL – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.
Earnings & Valuation
This table compares Accuray and Nexgel’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Accuray||$396.29 million||0.80||-$6.31 million||($0.13)||-26.38|
Insider and Institutional Ownership
70.4% of Accuray shares are held by institutional investors. 4.0% of Accuray shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Accuray and Nexgel’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for Accuray and Nexgel, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Accuray presently has a consensus price target of $7.50, suggesting a potential upside of 118.66%. Nexgel has a consensus price target of $6.00, suggesting a potential upside of 217.46%. Given Nexgel’s higher probable upside, analysts clearly believe Nexgel is more favorable than Accuray.
Nexgel beats Accuray on 5 of the 8 factors compared between the two stocks.
About Accuray (Get Rating)
Accuray Incorporated develops, manufactures, and sells radiotherapy systems for alternative cancer treatments in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
About Nexgel (Get Rating)
NexGel Inc. is a provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. The company developed and manufactured electron-beam, cross-linked hydrogels. NexGel Inc. is based in Langhorne, Pa.
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.